In This Section

Building an Effective Mentorship Team: Essential Strategies at Every Stage in Your Career

Tuesday, April 12, 5:30 – 7 p.m. CST 

Carondelet, New Orleans Marriott

Organized as a collaborative effort between the Associate Member Council (AMC), Minorities in Cancer Research (MICR) Council, Women in Cancer Research (WICR) Council, and the AACR Science Education and Career Advancement Committee, this session features cancer researchers with a strong commitment to mentoring and supporting the professional development of cancer research investigators.

Did you participate in this Professional Advancement Session during the AACR Annual Meeting? If so, don’t forget to complete the session evaluation and share your feedback with us! Your input will help us shape additional professional development-related sessions and programming. Share your feedback!


Session Co-Chairs: 

Kathleen W. Scotto, PhD, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Beverly D. Lyn-Cook, PhD, FDA-NCTR (National Center for Toxicological Research), Jefferson, Arkansas

Please contact us at [email protected] with any questions.

Navigating a successful career in cancer research, whether in academia, industry, or government can be daunting.  Establishing a team of mentors to guide you along the way is an essential step as you begin your journey. This session features cancer researchers with a strong commitment to mentoring and supporting the professional development of cancer research investigators. Hear their stories and learn how to build and take full advantage of an effective mentoring team, whether you are a trainee, an early-stage investigator, or a later-stage investigator considering a career change.

2022 Participating Senior Scientists

Oliver Bogler, PhD

Oliver Bogler, PhD

Director, Center for Cancer Training

National Cancer Institute

Bethesda, Maryland

Oliver studied Natural Sciences at Cambridge University, completed his PhD at the Ludwig Institute for Cancer Research in London and did post-docs at the Salk Institute, and the Ludwig Institute, San Diego. He was on faculty at Virginia Commonwealth University, Henry Ford Hospital and the University of Texas MD Anderson Cancer Center where he also served as director of basic research for the Brain Tumor Center. His work focused on EGFR signaling and novel platinum compounds in glioblastoma. In 2010, he became MD Anderson’s vice president for global academic programs and fostered cancer research and training across the globe. In 2011, he was also appointed senior vice president for academic affairs, stewarded MD Anderson’s education mission and oversaw 300 people who supported 1,700 faculty and more than 2,000 trainees. In 2018, he became COO at the ECHO Institute at the University of New Mexico. In 2020, he joined the NCI as director of the Center for Cancer Training.



Upjohn Professor of Pharmacology, Professor of Neuroscience, Department of Neuroscience,

Brown University

Providence, Rhode Island

Dr. Wayne Bowen earned his BS in chemistry from Morgan State College in 1974, and his PhD in biochemistry and neurobiology at Cornell University in 1981. After postdoctoral studies at the National Institute of Mental Health (NIMH), he earned his BS in chemistry from Morgan State College in 1974, and his PhD in biochemistry and neurobiology at Cornell University in 1981. After postdoctoral studies at the National Institute of Mental Health (NIMH), he moved to Brown University in 1983, as assistant professor of biology in the Section of Biochemistry where he taught and conducted research on opioid and sigma receptors in the brain. He moved back to the NIH in 1991 to establish the Unit on Receptor Biochemistry and Pharmacology within the Laboratory of Medicinal Chemistry of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). He returned to Brown University in 2004 to take a position as professor of biology in the Department of Molecular Pharmacology, Physiology and Biotechnology in the Division of Biology and Medicine. In 2007, he assumed the position as department chair and was named Upjohn professor of pharmacology in 2008. He moved to the Department of Neuroscience in 2021.  Dr. Bowen is a nationally recognized leader in research on sigma receptors; membrane proteins found in tissues throughout the body and that are highly upregulated in cancer cells. He is credited with the discovery of the sigma-2 receptor and subdividing the system into sigma-1 and sigma-2 subtypes. He demonstrated that sigma-2 receptor ligands induce apoptotic cell death or alter cellular metabolism, suggesting a role for the system in cell survival. Dr. Bowen has published over 150 peer-reviewed journal articles on topics related to sigma and opioid receptors. This research has been funded by NIDA, NINDS, NIDDK, NIGMS, the Rhode Island Science and Technology Advisory Council, a Salomon Award from Brown University, and the Upjohn Professorship in Pharmacology. 

“Work hard, give your best, and don’t be afraid to fail.”

Victoria M. Richon, PhD

Victoria M. Richon, PhD

Special R&D Advisor

Ribon Therapeutics, Inc.

Cambridge, Massachusetts

Victoria Richon, Ph.D. serves as R&D advisor to the board of directors and chair of Ribon’s scientific advisory board. Previously, Dr. Richon served as Ribon’s president and as a member of the board of directors since the company’s founding in November 2015 to February 2022, and served as chief executive officer from January 2017 to February 2022. Prior to becoming Ribon’s chief executive officer, Dr. Richon served as the company’s chief scientific officer from November 2015 to January 2017. Prior to joining Ribon, Dr. Richon served as vice president, global head of oncology research and translational medicine at Sanofi Oncology from November 2012 to October 2015. Dr. Richon served as the vice president of biological sciences at Epizyme, Inc. from October 2008 to November 2012. Dr. Richon served as the senior director and head of the Cancer Biology and Therapeutics Department at Merck & Co. from 2004 to 2008. Dr. Richon serves on the board of directors of Epizyme, Inc and HotSpot Therapeutics, Inc. Dr. Richon received a B.A. in chemistry from the University of Vermont and a Ph.D. in biochemistry from the University of Nebraska Medical Center.

John H. Stewart IV, MD, MBA

John H. Stewart IV, MD, MBA

Founding Director, Louisiana State University New Orleans – Louisiana Children’s Medical Center Cancer Center

Louisiana State University School of Medicine, New Orleans

New Orleans, Louisana

Dr. John H. Stewart, IV, MD, MBA, is the founding director of the Louisiana State University- Louisiana Children’s Medical Center Cancer Center. He also holds the rank of professor of surgery at the Louisiana State University New Orleans School of Medicine. Under his leadership, Dr. Stewart sets the overall mission, vision and direction for multidisciplinary cancer care and cancer clinical research programs for LSU Health New Orleans and LCMC Health. Before he arrived at LSU, Dr. Stewart served as the deputy director for the University of Illinois Cancer Center and physician executive for oncology services for the University of Illinois Health System. He was also a member of the initial class of Presidential Scholars for the University of Illinois. Dr. Stewart’s previous leadership roles include serving as the chief of surgery at the Durham VAMC, vice-chair in the Wake Forest School of Medicine Department of Surgery, and associate dean for clinical research and innovation at the Wake Forest University School of Medicine. He has published over 100 manuscripts in peer-reviewed journals, including Cancer, Annals of Surgery, JAMA Surgery, the Journal of the American College of Surgeons, the Journal of Thoracic and Cardiovascular Surgery, the Journal of Immunotherapy, Annals of Surgical Oncology, the Journal of Surgical Research, Transplantation, Surgery, and Cancer Gene Therapy.